Genetic Factors Underlying Tacrolimus Intolerance After Liver Transplantation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 17

PMID 36248867

Authors

Yuan Liu

Rui Wang

Peizhen Wen

Wenbin An

Jinxin Zheng

Tao Zhang

Pengshan Zhang

Haoyu Wang

Fan Zou

Hui Pan

Junwei Fan

Zhihai Peng

Affiliations

Soon will be listed here.

Abstract

Background: Tacrolimus (FK506) is the cornerstone of immunosuppression after liver transplantation (LT), however, clinically, switching from FK506 to cyclosporine (SFTC) is common in LT patients with tacrolimus intolerance. The aim of this study was to investigate the genetic risk of patients with tacrolimus intolerance.

Methods: A total of 114 LT patients were enrolled in this retrospective study. SNPs were genotyped using Infinium Human Exome-12 v1.2 BeadChip, and genome-wide gene expression levels were profiled using Agilent G4112F array.

Results: SFTC was a potential risk factor of dyslipidemia (OR=4.774[1.122-20.311], = 0.034) and insulin resistance (IR) (OR=6.25[1.451-26.916], = 0.014), but did not affect the survival of LT patients. Differential expression analysis showed donor , , , and , four important pharmacogenetic genes were significantly up-regulated in the tacrolimus intolerance group. Twelve SNPs of these four genes were screened to investigate the effects on tacrolimus intolerance. Regression analysis showed donor rs4646450 (OR=3.23 [1.22-8.60] per each A allele, = 0.01), donor rs6977165 (OR=6.44 [1.09-37.87] per each C allele, = 0.02), and donor rs776746 (OR=3.31 [1.25-8.81] per each A allele, = 0.01) were independent risk factors of tacrolimus intolerance.

Conclusions: These results suggested that SFTC was a potential risk factor for dyslipidemia and IR after LT. Besides, rs4646450, rs6977165, and rs776746 of might be the underlying genetic risks of tacrolimus intolerance. This might help transplant surgeons make earlier clinical decisions about the use of immunosuppression.

Citing Articles

Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.

Zhang T, Chen X, Liu Y, Zhang L PeerJ. 2024; 12:e18360.

PMID: 39465171 PMC: 11512548. DOI: 10.7717/peerj.18360.

References

Staatz C, Goodman L, Tett S . Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49(3):141-75. DOI: 10.2165/11317350-000000000-00000. View

Liu X, Yu L, Fu S, Xu J, DU C, Deng W . [Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients]. Nan Fang Yi Ke Da Xue Xue Bao. 2007; 27(7):1090-2. View

Lee D, Lee H, Yoon H, Yee J, Gwak H . Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics. 2022; 14(2). PMC: 8877595. DOI: 10.3390/pharmaceutics14020261. View

Coste G, Lemaitre F . The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics. 2022; 14(2). PMC: 8878862. DOI: 10.3390/pharmaceutics14020379. View

Thoefner L, Rostved A, Pommergaard H, Rasmussen A . Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2017; 32(1):69-77. DOI: 10.1016/j.trre.2017.03.004. View

Emre S, Genyk Y, Schluger L, Fishbein T, Guy S, Sheiner P . Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int. 2000; 13(1):73-8. DOI: 10.1007/s001470050012. View

MacPhee I, Fredericks S, Tai T, Syrris P, Carter N, Johnston A . Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002; 74(11):1486-9. DOI: 10.1097/00007890-200212150-00002. View

Scalea J, Levi S, Ally W, Brayman K . Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol. 2015; 12(3):333-42. DOI: 10.1586/1744666X.2016.1123093. View

Liu Y, Zhang T, Li C, Ye L, Gu H, Zhong L . SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients. Biomark Med. 2017; 11(8):607-618. DOI: 10.2217/bmm-2017-0128. View

10.

Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson B, Tsochatzis E, Gurusamy K . Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev. 2017; 3:CD011639. PMC: 6464256. DOI: 10.1002/14651858.CD011639.pub2. View

11.

Onizuka M, Kunii N, Toyosaki M, Machida S, Ohgiya D, Ogawa Y . Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2010; 46(8):1113-7. DOI: 10.1038/bmt.2010.273. View

12.

OGrady J, Burroughs A, Hardy P, Elbourne D, Truesdale A . Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002; 360(9340):1119-25. DOI: 10.1016/s0140-6736(02)11196-2. View

13.

Abouljoud M, Anil Kumar M, Brayman K, Emre S, Bynon J . Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant. 2002; 16(3):168-72. DOI: 10.1034/j.1399-0012.2002.01054.x. View

14.

Lazzaro C, McKechnie T, McKenna M . Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses. J Nephrol. 2002; 15(5):580-8. View

15.

Liu J, Ouyang Y, Chen D, Yao B, Lin D, Li Z . Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients. Int Immunopharmacol. 2018; 57:18-24. DOI: 10.1016/j.intimp.2018.02.005. View

16.

Ogino S, Hashikura Y, Katsuyama Y, Ikegami T, Nakazawa Y, Urata K . Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. Transplant Proc. 2004; 36(2 Suppl):299S-301S. DOI: 10.1016/j.transproceed.2003.12.037. View

17.

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

18.

Beckebaum S, Klein C, Varghese J, Sotiropoulos G, Saner F, Schmitz K . Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment Pharmacol Ther. 2009; 30(8):834-42. DOI: 10.1111/j.1365-2036.2009.04099.x. View

19.

Xie H, Wood A, Kim R, Stein C, Wilkinson G . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004; 5(3):243-72. DOI: 10.1517/phgs.5.3.243.29833. View

20.

Meirelles Junior R, Salvalaggio P, de Rezende M, Evangelista A, Della Guardia B, Matielo C . Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015; 13(1):149-52. PMC: 4977591. DOI: 10.1590/S1679-45082015RW3164. View